PRODUCTION OF PEGYLATED FRAGMENTS OF GD2-SPECIFIC ANTIBODIES THAT INDUCE DIRECT CELL DEATH OF GD2-POSITIVE TUMOR CELLS, AND THEREOF USE IN THE TREATMENT OF GD2-POSITIVE TUMORS

摘要

The invention relates to biotechnology and pharmacy, and specifically to the creation of a multivalent protein structure of a new format on the basis of a plurality of antibody fragments conjugated with a polyethylene glycol molecule and having an affinity for ganglioside GD2. Such a structure can be used as an active substance in pharmaceutical compositions intended for the treatment of many types of oncological diseases characterized by the expression of ganglioside GD2 on the surface of tumor cells, such as neuroblastoma, small-cell lung cancer, sarcoma, glioma, retinoblastoma, melanoma, and others. The new therapeutic agent described has a number of advantages over monoclonal antibodies against ganglioside GD2, such as multivalence and the absence of undesirable effector functions, and therefore can provide a high level of effectiveness and safety when used in clinical practice.